Benzinga | Jan 19, 2021 07:43AM EST

Accuray Highlights Publication Of Data Showing TomoTherapy Provides Long-Term Control Of Low-Risk Breast Cancer

SUNNYVALE, Calif., Jan. 19, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control seven years after receiving once-daily accelerated partial breast irradiation (APBI) delivered with the TomoTherapy(r) System. The study, published online in the International Journal of Radiation Oncology*Biology*Physics, also reported that the once-daily schedule was associated with a very low incidence of acute and late toxicities.